Breadcrumb

Breadcrumbs

Oncology Main Article

Oncology

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.

Anchored by our Antibody Drug Conjugate (ADC) and Acute Myeloid Leukemia (AML) franchises, our cancer pipeline includes more than 20 small molecules, monoclonal antibodies and ADCs stemming from our powerful research engines: our two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. 

We are committed to identifying the right resources and collaborations to become a leader in oncology. In addition to identifying ways to accelerate the development of compounds currently in our pipeline, we will continue to discover new compounds utilizing our in-house science expertise, collaborate with industry and academic partners, and acquire or in-license compounds that align with our strategy.

These are investigational agents and are not approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.

ADC Franchise More Stories Content

More Stories

ADC Franchise

An antibody drug conjugate (ADC) is a type of targeted cancer medicine that delivers chemotherapy (“payload”) directly to cancer cells via a linker

read more ...